Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Schering-Plough hails ‘important treatment option’ for asthma in children

Schering-Plough hails ‘important treatment option’ for asthma in children

5th February 2008

Schering-Plough has reported that Asmanex (mometasone furoate inhalation powder) is a key treatment option for children aged four to 11 with asthma.

The company notes that asthma is the most common chronic condition among children and adds that, taken daily, maintenance inhalers help reduce symptoms of the condition.

Asmanex is delivered via the Asmanex Twisthaler, which uses an inhalation-driven device without the use of a propellant, eliminating the need for hand-breath coordination and offering a numeric dose counter to provide visual confirmation on the unit of the remaining doses.

The Asmanex Twisthaler 110 mcg was approved for use in children aged four to 11 by the US Food and Drug Administration this week.

Robert J Spiegel, chief medical officer and senior vice-president of Schering-Plough Research Institute, said: “As the first inhaled corticosteroid that is approved for once-daily dosing in children as young as age four, the approval of the paediatric indication for Asmanex provides an important treatment option for children with moderate and mild persistent asthma.”

The company adds that updated guidelines from the National Asthma Education and Prevention Programme state that inhaled corticosteroids are the preferred foundation treatment for children with persistent asthma to gain long-term control over their symptoms.

In August 2006, Schering-Plough announced an global partnership agreement with Novartis for the development of a once-daily, fixed-dose combination therapy for chronic obstructive pulmonary disease and asthma.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.